Treatment of resistant hypertension

Journal of Hypertension

Volumn 28, Issue 11, 2010, Pages 2194-2195

  Pimenta, Eduardo ^a   Calhoun, David A ^b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b and Clinical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; SPIRONOLACTONE;

ADD ON THERAPY; ALDOSTERONE BLOOD LEVEL; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CARDIAC PATIENT; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; HYPERTENSION; LOW DRUG DOSE; NOTE; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RESISTANT HYPERTENSION; TREATMENT OUTCOME;

EID: 77958510036     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32833eafa3     Document Type: Note

References (17)

1. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008; 51:1403-1419.
2. Egan BM, Zhao Y, Rehman SU, Brzezinski WA, Clyburn B, Basile JN, et al. Treatment resistant hypertension in a community-based practice network. J Clin Hypertens 2009; OR-12:A6; (abstract).
3. Cuspidi C, Macca G, Sampieri L, Michev I, Salerno M, Fusi V, et al. High prevalence of cardiac and extracardiac target organ damage in refractory hypertension. J Hypertens 2001; 19:2063-2070.
4. Pierdomenico SD, Lapenna D, Bucci A, Di Tommaso R, Di Mascio R, Manente BM, et al. Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant and true resistant hypertension. Am J Hypertens 2005; 18:1422-1428.
5. Pimenta E, Gaddam KK, Oparil S, Aban I, Husain S, Dell'Italia LJ, et al. Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. Hypertension 2009; 54:475-481.
6. Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27:2121-2158.
7. Ernst ME, Carter BL, Goerdt CJ, Steffensmeier JJ, Phillips BB, Zimmerman MB, et al. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension 2006; 47:352-358.
8. Pimenta E, Calhoun DA, Oparil S. Etiology and pathogenesis of systemic hypertension. In: Crawford MH, DiMarco JP, Paulus WJ, editors. Cardiology. Philadelphia: Elsevier; 2009. pp. 511-522.
9. Chapman N, Dobson J, Wilson S,Dahlof B, Sever PS, WedelH, etal. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007; 49:839-845.
10. Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003; 16:925-930.
11. Ouzan J, Perault C, Lincoff AM, Carre E, Mertes M. The role of spironolactone in the treatment of patients with refractory hypertension. Am J Hypertens 2002; 15:333-339.
12. de Souza F, Muxfedlt E, Fiszman R, Salles G. Efficacy of spironolactone therapy in patients with true resistant hypertension. Hypertension 2009; 55:147-152.
13. Lane DA, Shah S, Beevers DG. Low-dose spironolactone in the management of resistant hypertension: a surveillance study. J Hypertens 2007; 25:891-894.
14. Sharabi Y, Adler E, Shamis A, Nussinovitch N, Markovitz A, Grossman E. Efficacy of add-on aldosterone receptor blocker in uncontrolled hypertension. Am J Hypertens 2006; 19:750-755.
15. Alvarez-Alvarez B, Abad-Cardiel M, Fernandez-Cruz A, Martell-Claros. Management of resistant arterial hypertension: role of spironolactone versus double blockade of the renin-angiotensin-aldosterone system. J Hypertens 2010; 28:2329-2335.
16. Gaddam KK, Nishizaka MK, Pratt-Ubunama MN, Pimenta E, Aban I, Oparil S, Calhoun DA. Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch Intern Med 2008; 168:1159-1164.
17. Eide IK, Torjesen PA, Drolsum A, Babovic A, Liledahl NP. Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. J Hypertens 2004; 22:2217-2226.